Biogen
BIIB
876 hedge funds and large institutions have $20.2B invested in Biogen in 2024 Q4 according to their latest regulatory filings, with 132 funds opening new positions, 300 increasing their positions, 322 reducing their positions, and 159 closing their positions.
1.96% more ownership
Funds ownership: 88.87% → 90.83% (+2%)
7% less repeat investments, than reductions
Existing positions increased: 300 | Existing positions reduced: 322
4% less funds holding
Funds holding: 917 → 876 (-41)
13% less call options, than puts
Call options by funds: $310M | Put options by funds: $356M
17% less first-time investments, than exits
New positions opened: 132 | Existing positions closed: 159
19% less capital invested
Capital invested by funds: $25.1B → $20.2B (-$4.84B)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$447M |
| 2 |
D.E. Shaw & Co
New York
|
+$198M |
| 3 |
VanEck Associates
New York
|
+$163M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$125M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$91.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$533M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$230M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$195M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$170M |
| 5 |
ClearBridge Investments
New York
|
-$101M |
BIIB Hedge Fund Activity: Q4 2024 in Review
876 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2024, worth a combined $20.2B — down 19% from $25.1B a quarter earlier.
Sellers outnumbered buyers: 159 funds closed out of BIIB and 132 opened new positions — a net loss of 27 holders — while 322 trimmed existing stakes and 300 added.
The largest buyer was Pacer Advisors, adding an estimated $447M. The largest seller was JP Morgan Chase, cutting an estimated $533M.
- 876 institutional investors held Biogen (BIIB) as of Q4 2024, down from 917 in Q3 2024.
- Funds reported $20.2B of Biogen stock for Q4 2024, down 19% quarter-over-quarter.
- 132 funds opened new Biogen positions in Q4 2024 and 159 closed out, a net change of -27 holders.
- The largest Biogen buyer in Q4 2024 was Pacer Advisors, an estimated $447M added.
- The largest Biogen seller in Q4 2024 was JP Morgan Chase, an estimated $533M sold.
Based on aggregated 13F filings for Q4 2024.